Orin Chisholm




Orin Chisholm is the Program Authority and Senior Lecturer in Pharmaceutical Medicine in the School of Medical Sciences at UNSW a position she has held since late 2012. After undergraduate studies in biochemistry at The University of Sydney and doctoral studies in molecular biology and oncology at the Children’s Medical Research Foundation, Orin followed a research and academic pathway for several years. She undertook research appointments at leading medical research institutes in New York, Melbourne, Canberra and Sydney, where her research focussed on a molecular understanding of haemopoiesis. She also expertise in undergraduate and postgraduate teaching in the areas of biochemistry, molecular genetics, immunology and biotechnology.

Orin has considerable work experience in the pharmaceutical industry, predominantly in the area of Regulatory Affairs, where she has over 12 years experience. She has worked in both large pharmaceutical and smaller biotechnology companies in Australia. She has particular expertise in the registration of biotechnology products for oncology indications. She also worked at Medicines Australia as their scientific manager during the initial consultation period for ANZTPA. She lectured from 2005-2012 at the University of Sydney in their Molecular Biotechnology program on the regulation of biotechnology products in Australia.

Orin is a member of ARCS, ASCEPT, DIA, RAPS and HERDSA. Her current research interests lie in the areas of regulatory science and the scholarship of learning and teaching in pharmaceutical medicine.

More info here.

Customize your search:

E.g., 2016-10-26
E.g., 2016-10-26
E.g., 2016-10-26
Sep 19th 2016

Learn about personalised medicine and the impact that our enhanced understanding of genetics has on modern medicine and society. Personalised medicine. Precision medicine. Individualised medicine. Customised medicine. Targeted medicine. All buzzwords of recent years that excite, confuse and infuriate the public, researchers and healthcare professionals. Broadly speaking, these terms all refer to the idea of tailoring treatment to individual patients based on their genetic code.

Average: 10 (1 vote)